| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Bicycle Therapeutics plc (NASDAQ: BCYC)
BCYC Technical Analysis
4
| As on 9th Jun 2023 BCYC STOCK Price closed @ 25.95 and we RECOMMEND Sell for LONG-TERM with Stoploss of 30.70 & Strong Sell for SHORT-TERM with Stoploss of 49.91 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BCYCSTOCK Price
| Open | 25.26 | Change | Price | % |
| High | 26.25 | 1 Day | 0.86 | 3.43 |
| Low | 25.00 | 1 Week | 1.97 | 8.22 |
| Close | 25.95 | 1 Month | 6.29 | 31.99 |
| Volume | 75300 | 1 Year | -31.26 | -54.64 |
| 52 Week High 60.87 | 52 Week Low 12.95 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| BCYC Daily Charts |
BCYC Intraday Charts |
Whats New @ Bazaartrend |
BCYC Free Analysis |
|
|
BCYC Important Levels Intraday
| RESISTANCE | 28.36 |
| RESISTANCE | 27.59 |
| RESISTANCE | 27.11 |
| RESISTANCE | 26.63 |
| SUPPORT | 25.27 |
| SUPPORT | 24.79 |
| SUPPORT | 24.31 |
| SUPPORT | 23.54 |
BCYC Forecast May 2024
| 4th UP Forecast | 46.94 |
| 3rd UP Forecast | 40.21 |
| 2nd UP Forecast | 36.05 |
| 1st UP Forecast | 31.89 |
| 1st DOWN Forecast | 20.01 |
| 2nd DOWN Forecast | 15.85 |
| 3rd DOWN Forecast | 11.69 |
| 4th DOWN Forecast | 4.96 |
BCYC Weekly Forecast
| 4th UP Forecast | 42.71 |
| 3rd UP Forecast | 37.34 |
| 2nd UP Forecast | 34.01 |
| 1st UP Forecast | 30.69 |
| 1st DOWN Forecast | 21.21 |
| 2nd DOWN Forecast | 17.89 |
| 3rd DOWN Forecast | 14.56 |
| 4th DOWN Forecast | 9.19 |
BCYC Forecast2024
| 4th UP Forecast | 121.18 |
| 3rd UP Forecast | 90.64 |
| 2nd UP Forecast | 71.76 |
| 1st UP Forecast | 52.88 |
| 1st DOWN Forecast | -0.98 |
| 2nd DOWN Forecast | -19.86 |
| 3rd DOWN Forecast | -38.74 |
| 4th DOWN Forecast | -69.28 |
Bicycle Therapeutics plc ( NASDAQ USA Symbol : BCYC )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BCYC Business Profile
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Address: Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service